|
 |
 |
| |
Composition:
Each capsule contains
Omeprazole…………………20
mg
Domperidone ………………10
mg
Description: - It is the prototype
member of a new class of substituted benzimidazoles,
which inhibit the final common step in gastric
acid secretion. The only significant pharmacological
action of omeprazole is dose dependent suppression
of gastric acid secretion; without anticholinergic
or H2 blocking action. It is a powerful inhibitor
of gastric acid: can totally abolish HCI secretion,
both resting as well as that stimulated by any
of the secretagogues, without much effect on pepsin,
intrinsic factor, juice volume and gastric motility.
Omeprazole is inactive at neutral pH, but at pH<5
rearranges to two charged cationic forms (a sulphenic
acid and a sulphenamide configurations) that react
covalently with the SH groups of the H+K+ATPase
enzyme and inactivate it irreversibly, specially
when two molecules of Omeprazole react with one
molecule of the enzyme. After diffusing into the
parietal cell from blood it gets concentrated
in the acidic pH are unable to diffuse back. Moreover
it gets tightly bound to the enzyme. These features
and the specific localization of H+K+ATPase to
apical membrane of the parietal cells confer high
degree of selectivity of action to Omeprazole.
Acid secretion resumes only when new H+K+ATPase
molecules are synthesized. Domperidone is a potent
dopamine antagonist with antiemetic properties.
It increases lower oesophageal sphincter pressure,
anterneal & duodenal contractions, gastric
emptying of liquids and semi-solids, and shortens
the stationary phase for solids in the stomach.
Indications:- Use in peptic ulcer
and hyperacidity problems. Reflux or ulcerative
oesophagitis. Zollinger-Ellison syndrome. NSAIDS-induced
ulcers.
Contra indications: - Hypersensitivity
and neonates.
Paediatrics: Not recommended
Pregnancy: Safety not established.
Lactation: Safety not established.
Dosage: - One or two capsules
twice a day or as directed by physician.
Presentation: - 10x10 capsules
in a Multicarton. |
|
|
 |
|
|
|
|
|
|